WHO scale for dehydration in children aged 1 month–5 years old.
\r\n\tKey Features:
\r\n\t*Reviews the basics of plating technology including electroless and immersion technologies
\r\n\t*Covers microjoining and nanojoining processes in various device applications
\r\n\t*Examines applications of microjoining such as the wafer level packaging, biomedical research, medical implants etc.
DNA vaccine is a third-generation vaccine, which encompasses a vector with eukaryotic cell promoter, and a gene, which encodes for an immunogenic protein. These vaccines have been shown to elicit a robust cytotoxic T cell in comparison with subunit vaccines. Also, DNA vaccine has the capacity to induce both cellular and humoral immune responses by utilizing MHC I and MHC II antigen presentation by DCs [1, 2, 3]. Although DNA vaccines are licensed for use in veterinary vaccines since 2005, they have their own limitation due to low transfection efficiency. As a result, they perform poorly in human clinical trials and require multiple booster doses to achieve desirable immune response [2, 4, 5]. With the advent of new adjuvant systems such as nanoparticles, the immunogenicity of DNA vaccines can be enhanced considerably [1]. DNA vaccines are being currently used against a wide variety of infectious diseases as well as cancer [3].
Surface receptors of T lymphocytes interact with antigens to mount an immune response [6]. For the antigenic features; alienation, molecular weight, the delivery route to the organism is very important. At the molecular level, these receptors interact with the phagocyte cell or infected target cell, which carries antigen on its surface bound to the major histocompatibility complex (MHC). While T cells do not recognize natural antigens, antigens must first be processed by antigen-presenting cells (APCs) and then presented to the T cells with the relevant MHC protein. T cells (cytotoxic T cells—Tc) with CD8 (cluster of differentiation 8) receptors recognize MHC I antigens, while T cells (helper T cells—Th) with CD4 receptor recognize antigens on MHC II. Macrophages are the first identified antigen-presenting cells. Then, dendritic cells and B cells were identified. T-cell receptors (TCRs) are proteins that have spread through the membrane extending from the cell surface to the outer periphery. Each cell carries thousands of the same receptor surface. TCRs recognize and bind only bound peptide antigens on MHC [7, 8].
MHC proteins are encoded by the respective gene in the genome of all the vertebrate animals. The human MHC proteins are called human leukocyte antigens (HLAs) (human MHC I antigens, HLA-A, B and C, human MHC II antigens, HLA-DR, DQ and DP). Because of the difference in MHC proteins between the tissue donor and recipient, they were first discovered with tissue transplant rejection. Even within a species, these proteins are not structurally the same because of differences in amino acid sequences, also known as polymorphisms. For this reason, it forms an important antigenic barrier in organ transplantation. MHC genes encode two classes of MHC proteins, class I and class II. While MHC class I protein is located on the surfaces of all the nucleated cells, MHC class II protein is located only on the surface of antigen-presenting cells (APCs), including B lymphocytes, macrophages and dendritic cells. The structure of the MHC I protein comprises of a relatively small size of the β-2 microglobulin protein with α1, α2 and α3 domains linked to each other by disulfide bonds. The α1 and α2 domains constitute the variable antigen-binding domain. MHC II protein is formed by α1, β1, α2 and β2 domains, each of which is attached to one of the non-covalent bonds, and α1 and β1 domains constitute the antigen-binding domain, which is a variable part [7, 9, 10].
MHC proteins carry proteins in the cell which they are in, on themself. Thus, if the cell is not infected, it will carry its own peptides on the MHC proteins. On the other hand, if the cell harbors a foreign pathogen or protein, it will contain foreign peptides on MHC proteins. The function of these MHC proteins is to allow T cells to recognize foreign antigen. The T cells constantly control the surface of other cells for foreign antigen presence and do not recognize foreign antigens unless they are presented through MHC proteins. No T cell interacts with MHC on a healthy cell surface, and self-attacking cells are eliminated during the development of tolerance. During antigen presentation, the MHC and peptide complex come out of the cell membrane and thus are recognized by the T cells. There are two different antigen presentations to T cells, MHC I and MHC II antigen presentation [7, 8, 9].
Peptides that are processed endogenously in the cytoplasm of non-phagocytic cells are presented with MHC I proteins. These antigens are derived from viruses or intracellular pathogens that infect cells, also known as internal antigens. In this pathway, for example, in a virus-infected cell, virus-associated proteins are primarily digested in the cytoplasmic proteasome. Peptide antigens of about 10 amino acids are delivered to the endoplasmic reticulum (ER), and a pore protein (TAP) produced by the two proteins acts in this stage. The peptides are bound to the MHC I protein, which results in the chaperone protein, which retains the MHC protein at that site. The resulting complex is released from the ER and goes to the cell surface and integrates into the membrane. This complex is recognized and bound by cytotoxic T cells. The CD8 receptor on the Tc cell surface strengthens it by adding the binding complex. This binding allows cytotoxic T cells to produce perforin and cytotoxic proteins that kill infected cells [7, 8, 10, 11].
The MHC II protein is produced only in cells that present phagocytic antigen. For example, if an extracellular pathogen such as a bacterium is engulfed and then peptide antigens are provided, then MHC II proteins are produced in the ER and accumulated therein blocked with Li proteins, which inhibit binding with other peptides. The MHC II-Li protein complex is transferred to lysozyme and then combined with the phagosome to form the phagolysosome. There are foreign pathogen antigens, pathogenic proteins including connective chaperones are digested to form peptides of 10–15 amino acids. The resulting pathogenic peptides are transferred to the cell surface by binding with MHC II. This complex is recognized by the TCR on the helper T cells; the CD4 coreceptor also binds to this complex and, through interaction with the Th cells, activates to produce cytokines. The produced cytokine activates antibody production by specific B-cell clones or causes inflammation [7, 8, 11].
The structure of plasmid DNA provides an advantage over other traditional protein-based or carbohydrate-based grafts in which it inherently possesses DNA vaccination. Immunogenesis from DNA vaccination takes a long time, and there is no pathogenicity caused by inactivated virus in DNA vaccines. The vaccine containing plasmid DNA (pDNA) can encode many immunogenic proteins of the same virus and can also encode similar proteins belonging to different infective agents [12]. Another important advantage is that the production of DNA vaccines is easier when compared to recombinant protein vaccines [13]. DNA vaccines prepared to make the cytokines more desirable to direct the immune system are more potent and suitable for stimulating the type of immunological response by cloning genes encoding the target cytokine and antigens into the same expression plasmids. DNA vaccines lead to sustained stimulation of antigen expression and the immune response leading to prolonged protective immunity [7]. Easy construction and manipulation of plasmid DNA are another important advantage of DNA vaccines [14].
DNA vaccines are stable at room temperature, are easy to obtain, are economical and are relatively more reliable than other vaccines. Plasmid DNA vaccines have been shown to be highly evaluated, safe and immunogenic in human clinical trials, even though they have no mental status [15]. However, it is necessary to increase transfection efficiencies of naked DNA vaccines, facilitate intracellular uptake, target into cells, and perform these operations with small amounts of DNA. Various gene delivery systems and adjuvant systems in the nanosphere are used to overcome these problems. During the use of nanotechnological adjuvant systems, the degradation of DNA is prevented, resulting in ultra-rapid delivery by targeting to desired cells [9, 16].
Viral-based gene delivery systems are carriers on which modifications are made to transfer therapeutic genes to target cells without creating viral disease. Viral gene carriers such as adenoviruses, adeno-associated viruses, lentiviruses and retroviruses exhibit an effective ability to transfer genetic material to the target cell with high gene transfer efficiency [17, 18, 19]. In viral gene delivery systems, the transferred genetic material either remains an episomal element or is integrated into the host chromosome. Desired genetic placement leads to persistent and stable protein expression but increases with the introduction of oncogenic potential mutagenesis [18, 20]. In addition, viral vectors being targeted to specific cell types, the limited availability of DNA, and the laborious and expensive large-scale production have led to a growing disincentive for the development of non-viral gene carriers. The safety risk is lower for non-viral carriers compared to viral gene carriers [18, 21, 22, 23, 24].
Physical gene transfection delivery systems are consisting of Non-viral gene delivery systems are in which pDNA is usually applied alone, which involves mechanical processes such as microinjection, biojector, pressure and particle bombardment (gene gun), ultrasound, magnetofection, photoporation (laser assisted), hydroporation (hydrodynamic forced), droplet-based microfluidic platforms for in vitro transfection and electrical processes such as electroporation [10, 11, 21, 23, 25]. In addition, ultrasound and microbubble-mediated plasmid DNA uptake is a fast, global and multi-mechanisms involved process [26, 27].
In microinjection, cell membrane or nuclear membrane is penetrated by simple mechanical force using a microneedle diameter of 0.5–5 μm, at a specific and reproducible depth with less physical pain than conventional DNA delivery. This gene delivery system is mainly used to inject DNA constructs in vivo. Application of DNA by this method leads to constant expression of the antigen encoded in the skin. This method can also be used to deliver DNA for a prolonged period of time, similar to the administration of drugs at a constant rate. In the method, usually the stratum corneum and the viable epidermis are breached by microneedles, after which DNA can be delivered into the dermis. There are several different microneedle methods for DNA delivery; solid microneedles can be coated with DNA prior to skin penetration, uncoated microneedles can be used to damage the epidermis prior to application of a transdermal patch containing the DNA of interest, solid microneedles constructed with biopolymers can be coated with DNA such that the needles dissolve upon contact with the fluid in the dermis to release DNA into the skin and hollow microneedles can deliver DNA into the dermis through the needles [28, 29, 30]. Quantitative introduction of multiple components into the same cell is an advantage of this technique, while technical skills are required to prevent cell damage [31].
The ballistic DNA delivery or DNA-coated particle bombardment (gene gun) that was first used for gene transfer to plants in 1987 uses heavy metal microparticles (e.g., gold, silver microparticles or tungsten, 1–5 μm in diameter) to hold nucleic acids and penetrate the target cells. Momentum allows penetration of these particles to a few millimeters of the tissue and then cellular DNA release. Gas pressure, particle size and dose frequency are critical factors in determining the degree of tissue damage and penetration effectiveness of the application [18, 28]. This method has various advantages such as safety, high efficiency against parenteral injection, total amount of DNA required for delivery is low, no receptor is required, size of DNA is not a problem and production of DNA-coated metal particles is easy to generate. A major disadvantage is that it induces greater immune responses than microinjection due to tissue damage with intradermal delivery, even in low doses, and also, gene expression is short term and low. This technique is a widely tested method for intramuscular, intradermal and intratumoral genetic immunization. The use of gene gun for gene therapy against various cancers in clinical trials has also been demonstrated [18, 28, 29, 30].
This device is commonly used to deliver medications through the skin for intradermal, subcutaneous and intramuscular applications. Usually, CO2 pressure is used to force medications (e.g., vaccine) loaded in the device through a tiny orifice, which creates a high-pressure stream capable of penetrating the skin in the absence of a needle [28, 29, 30]. Biojectors have been used to deliver different kinds of vaccines such as DNA vaccine, in preclinical studies and human clinical trials to elicit significantly higher antibody responses and cell-mediated immunity (CMI) to the conventional (needle and syringe) vaccine delivery systems [29]. Because biojector-based delivery systems can increase the uptake of DNA in tissues of the skin and muscle, efficacy of the DNA vaccine is considerably increased. In a phase 1 trial for HIV vaccine, the success demonstrated with biojector used to enhance the efficiency of DNA transfection coupled with the fact that biojectors do not use needles that will most likely lead to the increased use of biojectors for DNA delivery in the clinic [28, 29, 30].
Electroporation was first studied on the degradation of cell membrane with electric induction in the 1960s. The first reported study is transfection of eukaryotic culture cells through electroporation in 1982 [18, 28]. In many subsequent studies, transfection was performed on animal and plant cells via electroporation [18]. This physical gene delivery technique uses electrical pulse to generate transient pores in the cell plasma membrane allowing efficient transfer of DNA into the cells. Pore formation occurs very rapidly, in approximately 10 ns. The size of the electric pore is estimated to be smaller than 10-nm radius. If the molecule is smaller than the pore size (as in oligonucleotides and chemical compounds), it can be transferred to the cell cytosol through diffusion [18, 28]. This method has been effectively applied in humans in order to enhance gene transfer and tested in several clinical trials such as prostate cancer [28, 30], leukemia [28], colorectal cancer [28], malignant melanoma [28, 30], brain carcinomas [28], Parkinson’s disease [28], Alzheimer’s disease [28] and depression [28]. When the parameters are optimized, this method is equally effective as viral vectors for in vivo application. But, the disadvantage is that it often results in a high incidence of cell death because of high temperature due to high voltage application. And also, transfection of the cells in large regions of the tissues is difficult [18, 28, 29, 30].
Ultrasound (US) is a promising tool for gene delivery that has been able to facilitate DNA transfection of cells. US-mediated delivery is of interest due to its potential for repeated application, organ specificity, broad applicability to acoustically accessible organs, low toxicity and low immunogenicity. Different kinds of studies have examined gene transfection in various types of cells in vitro and with various organs and tissues in vivo, including brain [26, 30], cornea [30], pancreas [30], skeletal muscle [26, 30], liver [26, 30], heart [26, 30] and kidney [26, 30]. The advantages are that only acoustic energy is introduced into the cellular environment, which avoids possible safety concerns associated with chemical, viral or other materials introduced and left behind by other methods. Also, US-mediated delivery has been seen in many kinds of cell types and so may be broadly applicable, in contrast to other methods that often require reformulation for specific cell types. Unlike chemical delivery systems, US-mediated DNA uptake is often shown to be non-endocytotic. Acoustic cavitation plays a major role in the cell membrane permeabilization that facilitates DNA uptake. US can possibly deliver plasmid DNA to the periphery of the cell nucleus and facilitate rapid transfection by altering the cytoskeletal network. However, US-based gene transfection studies are still in preclinical trials and have the major challenge of relatively low transfection efficiency compared to optimal complexed chemical formulations and viral gene delivery systems [26, 28, 30].
The use of ultrasonication with the microbubble technique has shown great potential for intracellular gene delivery. The microbubble-cell membrane interaction serves as the key element bridging the acoustic conditions and the endpoint delivery outcomes. However, since the fundamental mechanical question of how plasmid DNA enters the intracellular space mediated by ultrasound and microbubbles is not fully understood, gene transfection efficiency is much lower than the potential for large-scale clinical needs [26, 27]. In one study, the gene transfection of human prostate cancer cell line (DU145) with fluorescently labeled DNA (pDNA gWiz-GFP) was studied after ultrasound exposure. In this process, different sonication conditions have been studied. DNA uptake, location of DNA during its intracellular trafficking and gene transfection efficiency after ultrasound exposure were followed for various periods by confocal microscopy and flow cytometry. As a result, ultrasounds delivered DNA into cell nuclei shortly after sonication and that the rest of the DNA cleared by autophagosomes/autophagolysosomes [26]. Also, ultrasound application combined with microbubbles has shown good potential for gene delivery. In one study, to unveil the detailed intracellular uptake process of plasmid DNA stimulated by ultrasound and microbubbles, the role of microbubbles in this process was investigated. So, targeted microbubbles were used to apply intracellular local stimulation on the cell membrane, and high-speed video microscopic recordings of microbubble dynamics were correlated with post-ultrasound 3D fluorescent confocal microscopic images fixed immediately after the cell. Two ultrasound conditions (high pressure, short pulse and low pressure, long pulse) were chosen to trigger different plasmid DNA uptake routes. Results showed that plasmid DNA uptake evoked by localized acoustically excited microbubbles was a fast (<2 min), global (not limited to the site where microbubbles were attached) and multi-mechanisms involved process [27].
The term adjuvant is derived from the Latin word “adjuvare” which means “help” or “develop.” Adjuvants are used to increase the life, quality and degree of the specific immune response developed against the antigens. At the same time, they have low toxicity and are capable of sustaining the immunological activity alone by inhibiting polymer accumulation in the cell [11, 32, 33]. So, they are preferred in vaccinations for newborns or adults. Also, they can stimulate a long-term immune response by reducing the amount of antigen that must be given in a single dose of vaccine [9, 34].
Adjuvants are classified according to the source of their constituents, their physicochemical properties or their mechanism of action and are generally grouped into two subheadings. One of them is molecular adjuvants that are immunostimulants (and also genetic adjuvants) (e.g., TLR ligands, cytokines, saponins and bacterial exotoxins that stimulate the immune response) and act directly on the immune system to enhance immune response against antigens. The other one is carrier systems; they are systems that promote vaccine antigens in the most appropriate way to the immune system while also exhibiting controlled release and depot effects, thereby increasing the immune response (e.g., mineral salts, emulsions, liposomes, virosomes, biodegradable polymer micro/nano particles and immune stimulating complexes—ISCOMs) [1, 9, 11, 34, 35, 36, 37, 38, 39].
Cytokines can also be delivered directly with the DNA vaccine, either on the same or on a separate expression plasmid as adjuvant duty. The effects of plasmid encoding cytokines such as interleukin IL-10, IL-12 or IFN-γ together with DNA vaccines have been studied in a variety of animal and disease models, up to clinical trials in humans [38]. Also, various studies describe the usage of plasmids coding for immune-signaling molecules, either as partial or as full-length genes. Many adjuvants function by activating the innate immune system via binding to Toll-like receptors (TLRs). Another innate immune mechanism, which is being explored for improving DNA vaccination, is the sensing of viral infections via pathogen recognition receptors (PRRs). Both proteins detect the presence of viral RNA in the cytosol. Co-delivery adjuvants with the vector coding for antigenic proteins result in significantly higher antibody titers as compared to the non-adjuvanted controls. Other strategies for genetic adjuvants include components of the complement system, protein aggregation domains, chemokines or co-stimulatory molecules. Whereas DNA vectors encoding certain cytokines have already entered clinical testing in humans, studies with many other genetic adjuvants were mostly performed in mice. Therefore, these promising studies should be optimized into powerful strategies to boost DNA vaccines in more complicated animals and humans [38].
Adjuvants can easily be internalized by the antigen-presenting cells (APCs) (macrophages and dendritic cells) because of their size being similar to pathogens (<10 μm) [11, 22, 25, 40]. The internalization and presentation of the adjuvant depends on the chemical and physical properties of the adjuvant system. It has been shown in various studies that the particles with cationic properties are more efficiently taken up by macrophages and dendritic cells [21, 24, 25, 41, 42, 43].
The characteristics that should be present in the adjuvants can be listed as follows: stability in an acidic, basic and enzymatic environment; retention of retained antigen or nucleic acid by constant release; systemic and mucosal immunity being effectively induced and balance between effective immunity and immunological tolerance at high doses [9, 44]. Also, the immunogenicity of weak antigens should increase the speed and duration of the immune response, cause only minimal local and systemic side effects, and be capable of a wide variety of vaccination with stability and ease of production. The ability to be effective in the living system of adjuvants depends on its ability to stimulate antigen-presenting cells (dendritic cells and macrophages) and T and B lymphocytes of the natural defense system [11]. There is a need for definitive information on the structure, stability, safety and immunogenicity of the adjuvant to be used in an effective vaccine development process [32, 33]. For this purpose, the choice of adjuvant depends on factors such as antigenic structure, immunization scheme, mode of administration and desired immune response pattern [33].
Nanoparticles are matrix systems called nanospheres or nanocapsules according to the method of preparation, which vary in size from 1 to 1000 nm and are prepared with natural or synthetic materials. They are also the matrix systems in which the active substance nucleic acid is solubilized, adsorbed or electrostatically interacted with the surface [23, 45].
In vaccine development studies, nanotechnology is becoming increasingly important. Numerous nanoparticles of varying composition, size, shape and surface properties are used to both increase vaccine efficacy and target vaccination. With these properties, nanoparticles play an active role in in vitro/in vivo drug and gene delivery systems. Because nanoparticles are biodegradable and easily recognizable by antigen-presenting cells (APCs), they can be easily endocytosed and used as successful vaccine carriers in vaccine delivery systems [22, 25, 40].
Nanoparticle-mediated delivery of DNA vaccines has the advantages of increasing transfection efficiency and immunogenicity, inducing both cellular and antibody responses, and not requiring special equipment during administration; there are some disadvantages, such as, the long-term effects of nanoparticles in the body are not yet known [1]. As a DNA vaccine carrier, natural polymeric nanoparticles such as chitosan, alginate, pullulan and inulin (2–1000 nm); synthetic polymeric nanoparticles such as PLGA, dendrimer, PLA, PHB and PEI (2–1000 nm); inorganic nanoparticles such as gold, silica-based and carbon-based nanoparticles (2–1000 nm); nano-liposomes (100–400 nm) which are phospholipids that can be organized in nanoscale and non-infectious virus-like particles (VLP) (20–800 nm) generated by packaging the nucleic acid into biocompatible capsid proteins [1, 9, 22] are used. In recent years, the use of complex nanoparticles to overcome the disadvantages of enhancing the function of single-source nanoparticles has been discussed. Polyethylene/PLGA, polyg-glutamic acid/chitosan, polyethylene/chitosan, dendrimer/polyethylene glycol, polyg-glutamic acid/polyethyleneimine (PEI), chitosan/tripolyphosphate and polyethylene glycol/liposome nanoparticles are remarkable DNA transport systems [1, 22, 25, 40, 46, 47]. The overall efficiency of nanoparticle-based DNA delivery systems depends on four basic factors. These factors explain the necessity of nanoparticle-based adjuvant systems. Accurate plasmid DNA is integrated with the nanoparticle into the target cell correctly, the nanoparticle is removed from the endosomal vesicles and is transferred to the cytoplasm, then is transferred to the mitochondria or nucleus [23, 25].
In recent years, there has been a tremendous improvement in the area of gene delivery system with the advent of cationic polymers. These polymers bind with nucleic acid(s) to form complex structures known as polyplexes, which have increased transfection efficiency [10, 48]. Some of the examples of the polycationic polymers are chitosan, polyethyleneimine (PEI), poly(2-hydroxy ethyl methacrylate) (pHEMA), polyamidoamine (PAMAM) dendrimers, polylactic-co-glycolic acid (PLGA), polyethylene glycol (PEG) and poly-L-lysine (PLL) and the negatively charged phosphate group of pDNA, which have cationic properties. [10, 23, 42, 43, 49, 50, 51]. Many factors such as molecular weight (MW), surface charge, charge density, hydrophilicity and morphology significantly influence the gene transfection efficiency of cationic polymers. For this reason, in general, optimization of various forms of these cationic polymers with pDNA is required to increase transfection efficiency. The polyplex structure electrostatically formed with DNA packs it into smaller structure, pDNA, that interacts effectively with the negatively charged cell membrane and is endocytosed easily into the cell. In addition, cationic polymers are suitable for specific applications like conjugation of targeted ligands and various moieties, which provide them with specific characteristics [21, 22, 24, 25, 52].
Since their discovery in 1964, liposomes are extensively studied and used in the pharmaceutical and cosmetic industries. It is a generic name for single- or multi-lamellar vesicles in lipid-based nano- and micro-dimensions, whose surface charge can be changed by lipid formulation. Thanks to biocompatibility, biodegradability, low toxicity and low immunogenicity, liposomes have been used as potential nucleic acid carriers both in vitro and in vivo systems. In the composition of cationic liposomes, neutral lipids, cationic lipids and/or anionic lipids can be complexed in different ratios for creating ideal co-lipid. Neutral lipids (DOPE, DPPC, DOPC and Chol) are also often involved in the cationic liposome structure for more efficient transport systems, although sometimes only cationic lipids (DOTAP, DC-Chol, MMRIE, DODAP, DDTAP and DDA) are used [8, 36, 53]. The choice of ideal co-lipids is important during the formulation phase [54, 55, 56], since they significantly affect the overall performance of cationic liposomes.
There is a strong correlation between morphology and performance of lipoplex (liposome and DNA complex). There are several models that determine morphology such as the external model (DNA is attached to the cationic liposome surface), the internal model (DNA is surrounded by the cationic liposomes), the cationic liposome beads model on the DNA sequence and the spherical model. In addition to the liposomal composition, cationic lipid/nucleic acid (N/P) load ratio, preparation methods, ionic strength and temperature also affect lipoplex formulation and morphology. While high N/P ratios accept that the lipid/DNA complex is compatible with the global model with effective DNA concentration [22, 54, 57, 58], the low N/P ratio accepts the model of cationic liposome beads on the DNA sequence. In addition, high concentrations of cationic liposomes can cause cytotoxicity. The particle size of the lipoplexes is also influential on transfection efficiency. In general, large lipoplexes are more effective with in vitro transfection of nucleic acids because large pieces allow rapid sedimentation, maximum cell contact with the cell membrane and easier separation after endocytosis. Small particles, on the other hand, are much more effective, safe and suitable for in vivo transport of nucleic acids [57, 59].
Various studies have shown that cationic liposomes (DC-Chol/DOPE) formed at various ratios of 3β-[N-(N′,N′-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol) and 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) are effective pDNA carriers in the preclinical as well clinical trials for plasmid transfection [55, 57, 60]. In another study, it was reported that the vaccine adjuvants with high immunogenicity were obtained with cationic liposomes formed at 50:50 ratio (50 mol%) with DC-Chol/DPPC (3β-[N-(N′,N′-dimethylaminoethane) carbamoyl] cholesterol/1,2-dipalmitoyl-sn-glycero-3-phosphocholine) [53]. In many studies, it has been reported that surface modifications to cationic liposomes (PEG-polyethylene glycol coating, etc.) increase transfection efficiency due to more stable plasmid retention, longer circulation time and lower immunological response. Studies have shown that transfection efficiency is increased by about 55% with PEG coating to protect surface charges [23, 48, 54, 56, 57, 61].
Chitosan is the best-known working polymer among the therapeutic natural polymers. It consists of D-glucosamine and N-acetyl-D-glucosamine units linked by β-(1,4) glycosidic bonds. The chitosan is derived from the chitin molecule and the thermoacetal deacetylation process forms the bonds. The chitin is a biopolymer in abundance in nature and is the cell wall of most of the fungi and bacteria of the shellfish and the outer shell of insects [62]. One of the most important applications of chitosan is its application as non-viral vector in gene therapy. For this reason, chitosan has recently been used for gene delivery systems for therapeutic purposes [50, 63]. The first chitosan/DNA complex was made about 25 years ago, and was composed of plasmid and chitosan in size of 150–600 nm. Positive charge, which allows it to complex easily with negatively charged DNA, allows the formation of nanocapsules (80–500) at various sizes that protect DNA from nuclease activation [64, 65].
Chitosan nanoparticles are formed by a wide variety of methods, by the formation of different bonds, by different polymer conformations and by various internal and external molecular interactions. In addition to covalent cross-linking and desolvation methods, ionic gelation is one of the most useful methods used in the handling of chitosan nanoparticles and is especially considered for polyelectrolyte sodium tripolyphosphate (TPP) [42, 43, 66]. In chitosan-based adjuvants, DNA is involved in structure determination, electrostatic interaction, encapsulation and surface adsorption [42, 50]. Chitosan has excellent biocompatibility, acceptable biodegradability, high biosecurity, low cytotoxicity and low immunogenicity. However, limited application of gene transport due to poor solubility at physiological pH, insufficient positive charge and low transfection efficiency can be prevented by various surface modifications on chitosan nanoparticles [25]. For example, TPP is useful in preparing chitosan nanoparticles and enhances its non-toxic nature. Due to the self-regulation nature of polycations and polyanions, it leads to the formation of linking complexes between TPP groups and chitosan amino groups. In the process of the protonation of the chitosan at physiological pH, TPP is covalently bound to chitosan amino groups providing structural change and better provocation [23, 50, 61, 67, 68].
Polyethyleneimine is a gene-carrying cationic polymer that has high transfection efficiency in vitro and in vivo with lower cost, but can exhibit high toxicity with concentration pulse [69, 70, 71]. PEI receives proton in aqueous solutions and has a high positive charge. Thus, in vitro and in vivo DNA and oligonucleotide transport are promising candidates as non-viral transport systems [71, 72]. PEI and its derivatives are commonly known as an effective dispersant and cationic flocculent used for negatively charged colloids [73].
Adjuvant systems with PEI involve the electrostatic interaction of DNA with the cationic polymer and the formation of the polycation/DNA complex [74]. The DNA/polymer complex (N/P) occurs when the amine group of this polymer interacts with the phosphate group of DNA [73]. In many studies, it has been shown that PEI has the advantages of holding pDNA with electrostatic bonds, binding to the cell surface and its endocytosis, and releasing pDNA into the cell. It also enhances the entry of the gene from cytoplasm to the nucleus [70]. This polymer is used for DNA-based immunotherapy or DNA vaccine delivery to ensure that the immune response is activated to provide a strong immune response [74]. Factors such as molecular weight, branching grade, ionic strength of solution, zeta potential and particle size affect the efficacy/cytotoxicity of PEI. PEI is coated with PEG and various ligands to increase transfection efficiency and reduce cytotoxicity. Meanwhile, the PEI in the linear structure helps to create an effective transport system than the branched PEI [69].
Dendrimers are nanometer-sized (1–100 nm) particles with a unique architectural structure in the form of spherical macromolecules, consisting of a central core, a hyperbranched mantle and a corona containing a peripheral reactive group. Dendrimers can be fabricated by convergent or divergent synthesis. The high-level control system on dendritic architectural synthesis makes dendrimers almost perfect spherical nanostructures with predictable properties. Dendrimers can build up ionic interactions with DNA, creating complexes with high stability and resolution. Costly production is the only disadvantage. Structures such as polyamidoamine and polypropylenimine are included in the dendrimeric classification [25, 75, 76, 77, 78].
Of the cationic compounds used in gene delivery, polyamidoamine (PAMAM) dendrimers have been regarded as the most suitable gene carrier, due to the presence of abundant amino groups on the electrostatically interacting surface with negatively charged nucleic acid material and low polydispersity. This association at the nanoscale (nucleic acid-dendrimer pair) is called dendriplex [79]. These particular supramolecular structures not only protect the genetic material from nuclease degradation but also interact with the negative surface of the cell membrane and activate entry into the cell through endocytosis. The high amine content of PAMAM dendrimers provides significant buffering capacity in the endosomal pH range. This extraordinary buffering capacity plays a powerful driving force in the liberation of dendriplex complexes prior to enzymatic degradation to lysosomal enzymes in endosomes. These properties make PAMAM dendrimers the carriers that are obliged to carry out future polycation-based gene delivery studies. On the other hand, long-term storage stability and high biocompatibility make PAMAM dendrimers almost necessary to use as gene carriers in vivo [24, 25, 49, 51, 61, 75].
The number of generations on the transfection efficiency is important. Dendrimer generations G0–G3, low-grade PAMAM dendrimers, exhibit low gene transfection efficiency and low cytotoxicity, while G4–G8 dendrimers show high transfection efficiency and high cytotoxicity. For this reason, dendrimer generations G4–G5, which have low cytotoxicity as well as high transfection efficiency in gene transfer, are preferred [25, 76]. In addition, adding different moieties enhances various features of dendrimers. For example, high amine content on the PAMAM surface allows conjugation of various materials to improve transfection efficiency and reduce target cytotoxicity [24, 25, 49, 61]. PEG conjugation provides positively charged protective sheath, which reduces cytotoxicity, undesired interactions with blood components, and facilitates binding of the ligand. Adding hydrophobic moieties favors hydrophilic-hydrophobic balance, reduced cytotoxicity and facilitation of packaging back into the vector. With glucocorticoid conjugation, nuclear targeting and parental dendrimers (dexamethasone and triamcinolone acetonide conjugates) provide hydrophilic-hydrophobic equilibrium modulation. By cyclodextrin conjugation, increase of endosomal escape and decrease of cytotoxicity as well as oligonucleotides against enzymatic digestion are protected. Finally, by amino acid, peptide and protein conjugation, it is also possible to increase cell penetration (arginine and TAT peptide conjugation), cellular uptake, endosomal escape, serum resistance (histidine conjugation), and nuclear localization, and also target specific receptors [24, 25, 51, 61, 77, 78].
PLGA is a solid polymeric material approved by the Food and Drug Administration (FDA) for nanoparticle-based drug and gene delivery systems. Their biocompatibility, biodegradability, reliability and high stability characteristics during storage provide advantages in delivery systems [20, 80, 81, 82]. PLGA nanoparticles can easily pass through vessels in vivo without damaging the tissues surrounding the tumor and thus accumulate with the mechanism of “enhanced permeability retention” (EPR) in solid tumors. However, PLGA particles are less efficient in encapsulating nucleic acids because hydrophobic properties of PLGA are not compatible with anionic, hydrophilic properties of nucleic acids. In addition, difficult preparation conditions and pH decreases during PLGA hydrolysis inactivate nucleic acid loading and prevent polyplex formation. In order to overcome these drawbacks, effective gene transfer systems can be formed with different formulations made with different molecular interactions [21, 48, 52, 61, 83, 84, 85, 86].
For example, PLGA nanoparticles can be processed with materials such as PEI to increase positive charge distribution and provide a stronger penetration of nucleic acid. After penetration of the nucleic acids, PEI, PEG cross-linking material and cell penetration peptides can be used for effective encapsulation and stabilization of the nano-carrier system [48, 81, 85]. It is also one of the systems to produce PLGA-based adjuvants in sizes of 200–300 nm by such means as cationic hydrophilic properties by condensing PLGA with cationic polymers such as polyethylenoxide (PEO) and polyethylene glycol methacrylate (PEGMA), emulsifying solvent diffusion method without shear stress [48, 81, 85].
In one study, DNA-loaded PLGA particles were fabricated by a double emulsion water in oil in water (w/o/w) method, in which energy is introduced to the system typically by either sonication or homogenization, and they were provided with submicron size (generally 0.1–10 μm). Then, conjugation of PLL to PLGA was achieved through the coupling agent at different percentages to create pDNA/PLGA/PLL (poly-l-lysine) complex. This system achieved effective gene transport by acquiring cationic adjuvant property. [87]. In another study, it has been reported that the PLGA particle, which is condensed with the cationic lipid DOTAP, provides efficient pDNA encapsulation by forming a cationic adjuvant system [88].
Polyethylene glycol (PEG) is a highly hydrophilic, non-immunogenic, semi-crystalline, linear polyether diol used as a non-ionic polymer consisting of ethylene oxide monomers. PEG, a polymer approved by the Food and Drug Administration (FDA), is non-toxic at low density and does not damage active proteins or cells. PEG is excreted completely through the kidneys (<30 kDa PEGs) or stool (>20 kDa PEGs) [89]. In addition, functionalities by conjugation of different terminal groups such as amino, carboxyl and sulfhydryl groups can be increased. It is soluble in aqueous solutions and in most organic solvents like methanol and dichloromethane [89].
The physical properties of the PEG material vary with the molecular weight. With an increase in the molecular weight, viscosity of PEG increases, while the water solubility decreases. Furthermore, the high solubility of PEG in organic solvents provides a great advantage in preparing solid dispersions. PEG provides stability to coating particles. The flexibility of the polymer chain, which allows the polymer units to rotate freely, ensures that the PEG protects the particles. Thanks to its high hydrophilic property, it creates a protective shield around the particulate. Nowadays, PEG is used not only to increase stability and circulation time of particles in vivo, but also to target particles to the desired areas [90].
In vivo transfection experiments with DC-Chol/DOPE liposomes with 1% PEG coating showed that the PEG coating increases the stability and longevity of the adjuvant, while it decreases the pH sensitivity and thus decreases the transfection rate. This pH sensitivity is important for the vaccination strategies carried out in the treatment of an existing tumor tissue [55]. However, there is no indirect disadvantage of PEG coating on the transfection rate, as there is no intention to improve the present tumor tissue, but there is no need for pH sensitivities for adjuvants in vaccine studies designed to protect against tumor formation [23, 54, 56, 61].
The pHEMA [poly(2-hydroxyethyl methacrylate)] polymer is the polymerized non-toxic form of HEMA (hydroxyethyl methacrylate) which is a toxic monomer. Hydrogels are hydrophilic and are capable of holding water up to thousands of times more than their own dry mass. For this purpose, pHEMA that is virtually uncharged is a three-dimensional hydrophobic polymer that can swell in water or biological fluids, and it can be used with a large number of pathways [91, 92]. Because of its high water content such as those in body cells, it is used in ureters, cardiovascular implants, contact lenses, tissue restorative surgical materials and many dental applications [93, 94]. pHEMA is also used in the pharmaceutical industry and in tissue engineering because of its biocompatibility and similar physical properties as living tissues [93]. In addition, the pHEMA polymer has been developed by virtue of its high biocompatibility properties and successful complexes formed by a wide variety of cationic compounds. It is also used in DNA purification, RNA adsorption and drug and enzyme transport [91, 95, 96]. These approaches shed light on the creation of new adjuvant systems for the transport of genetic material using pHEMA [91, 93, 97].
In our previous studies, we purposed to develop new pHEMA-based adjuvant systems to increase the immune effectiveness and protectivity of the DNA vaccine. Within this scope, cationic pHEMA-His/PEG, pHEMA-Chitosan/PEG, pHEMA-PEI/PEG and pHEMA-DOTAP/PEG particles were developed. As a result, all pHEMA-based adjuvant systems, which can be produced in nano-sizes and in the desired properties, have been shown to increase in vitro transfection efficiency compared to naked DNA by using them in different pDNA/adjuvant formulation ratios. When compared to Lipofectamine 2000 agent, pHEMA-PEI and pHEMA-DOTAP adjuvant formulations are promising candidates for gene transfection agents [98].
Advances in adjuvant systems have led to the development of biodegradable, environmentally responsive and biocompatible vaccine carriers (e.g., droplet-based microfluidic devices). An ideal adjuvant system should effectively interact with both the pDNA and cellular membrane and should not elicit an immune response or cytotoxicity. Characterization studies of pDNA vaccine-loaded delivery systems are carried out by size and zeta potential measurements, transmission electron microscopy (TEM), scanning electron microscopy (SEM), atomic force microscopy (AFM), gel retardation assay with agarose gel electrophoresis, PicoGreen assays, robustness assays and FT-IR [26, 31, 99, 100, 101, 102].
Cellular uptake adjuvant/nucleic acid formulations mainly depend on type, size, shape as well as composition, surface chemistry and/or the carrier charge. These are key factors, which affect carrier/cell interactions and the transfection efficiency. Cellular uptake of nucleic acid-loaded delivery systems and their localization in 2D (monolayer culture) and 3D (multicellular tumor spheroids) in vitro cell culture models and also in vivo models are studied by multi-labeling 3D confocal fluorescence microscopy, flow cytometry, overlaid bright field fluorescence microscopy based on GFP expressions, luciferase assays and fluorescence images [26, 27, 100, 101, 102].
Molecular adjuvants can be defined as plasmids expressing cytokines, chemokines or co-stimulatory molecules which can be co-administered with the antigenic DNA vaccine plasmid [103] or vaccine plasmid can be constructed as a bicistronic vector system. The magnitude of immune response after DNA vaccination is very closely related to: (i) the source of Ag presentation, (ii) the immunological properties of the DNA itself and (iii) the role of cytokines in eliciting the immune responses [104]. Thus, with the cells transfected by molecular adjuvant, encoding plasmids secrete the adjuvant into the surrounding region stimulating both local antigen-presenting cells (APCs) and cells in the draining lymph node, especially dendritic cells. The examples of molecular adjuvants as cytokines: GM-CSF (granulocyte-macrophage colony stimulating factor), M-CSF, IFN-γ, IL-2, IL-4, IL-7 and IL-8, IL-10, IL-12, IL-15, IL-18; as chemokines: IL-8, MCP-1 (monocyte chemoattractant protein 1), MIP-1a (macrophage inflammatory protein), RANTES (CCL5); and as co-stimulatory proteins: CD40L, CD80/86, ICAM-1 (intercellular adhesion molecule 1) [103]. In addition, ligands of pattern recognition receptors (PRRs) are described as molecular adjuvants. There are 13 TLR genes (TLR1–TLR13). TLR3 and TLR9 recognize dsRNA and ssDNA, respectively, and their ligands have been shown to act as molecular adjuvants. Poly(I:C) is a classical TLR3 ligand, and CpG is a TLR 9 ligand, showing molecular adjuvant properties via increasing cytotoxic T-cell responses [105]. Bcl-xL anti-apoptotic protein was also described as molecular adjuvant. Inhibiting the apoptosis of antigen-presenting dendritic cells, the cytotoxic T-cell responses (CD8+ T cells) are increased due to the longer survival of the dendritic cells [106]. In addition, rather than co-transfection, expression of Bcl-xL in a bicistronic vector further enhances CD8+ T-cell responses compared to co-transfection [107, 108].
In our previous studies, pIRESEGFP/Bcl-xL is a bicistronic vector bearing CMV (cytomegalovirus) promoter and IRES (internal ribosomal entry site) used as a backbone for DNA vaccination studies. Bcl-xL anti-apoptotic protein in frame with eGFP (enhanced green florescence protein) as a molecular adjuvant was also encoded by the plasmid. It’s shown that Bcl-xL anti-apoptotic protein rescued cells from serum deprivation, doxorubicin, camptothecin and staurosporine induced apoptosis [71, 109], induced prolonged expression of the antigen of interest in expressed under CMV promoter that facilitates an increased CD8+ T cell response in DNA vaccination studies encoding foot and mouth disease multi-epitopes [4] and Toxoplasma gondii, SporoSAG antigen [5].
In this chapter, we have discussed DNA vaccines, several widely used and emerging gene delivery systems to increase efficacy of DNA vaccines, characterization of these systems and cellular uptake of DNA vaccines yet to be tested in the clinic in the future. Also, as means of molecular adjuvants, several agents are in consideration like chemokines, cytokines, co-stimulatory molecules, PPR ligands and anti-apoptotic proteins.
Nanotechnology offers new strategies in formulating better adjuvants for DNA vaccines. However, they are very stable and the long-term cytotoxic effects in the body appear to be a potential problem. In order to remove this problem, most effective surface and content modifications of nanoparticles studied are being made. The relatively short history of the use of nanoparticles has led to a lack of understanding of the safety profile of human use. For this reason, many studies are being carried out in this regard today. If a safe profile can be shown as a result of these studies, this new vaccine delivery system will be considered to be an effective method, which will be widely used. In addition, nanoparticle-based DNA vaccines are seen as a strategy for future single-dose applications and the need for needle-free vaccines, as they enhance cell transfection efficiency and immunogenicity and enable targeting strategies.
In future studies, the development of nanoparticle-based gene delivery systems for different purposes will continue to be critical. Modification of toxicity and immunogenicity problems of viral vectors, enhancement of transfection efficiency as much as possible for non-viral vectors, enhancement of vector targeting and specificity, regulation of gene expression and identification of synergies between gene-based agents and other cancer therapies are promising studies. Nevertheless, the safe and efficient transport of plasmid DNA to initiate immunological responses remains an important barrier to human DNA vaccination. The development of new non-viral strategies for DNA vaccines has to continue to serve as biological insight and clinic-related methods. Specific concerns include difficulties with transfection of dendritic cells. This includes methods that target strong antigen signaling, antigen-presenting cell uptake and lymph node transduction without sacrificing biocompatibility. Carriers must deliver the genetic load specifically to the target tissue, while protecting the genetic material from metabolic and immune pathways.
DNA transfection of cells in vitro/in vivo studies requires overcoming both extracellular and intracellular barriers to gene transport from cell plasma membrane which is the barrier of intracellular DNA uptake and hinders DNA trafficking in the cytoplasm, and also into the cell nucleus that is nuclear envelope. Therefore, gene delivery methods including viral, non-viral, physical, chemical and molecular systems should facilitate DNA delivery across these barriers and into the nucleus to enable transcription without any degradation very quickly. Gene delivery systems are so important that besides the characterization of these systems by various methods such as SEM, TEM, AFM and FT-IR, the examination of their cellular uptake by various techniques like confocal complex fluorescence microscopy and flow cytometry and the development of study done in this area are extremely important in the future.
Dehydration is the main clinical manifestation and the most frequent complication in pediatric patients with AGE. It remains to be a common reason for ED visits, and it can lead to significant morbidity and mortality rates [1]. Management of gastroenteritis is based mainly on the proper assessment of dehydration severity and correction of dehydration.
In newborn babies, 75–80% of the total body weight constitutes the total body water (TBW) (varies with the gestational age), which decreases to 67% of body weight (2/3) after the neonatal period. There is a further decrease that reaches 60% by the end of the first year, and this percentage remains the same during the rest of life. After puberty and in adulthood, TBW is 60% in males and 55% in females. The TBW is divided into two components throughout the body: intracellular fluid compartment (ICF), which constitutes 40% of TBW, and extracellular fluid (ECF), which forms the remaining 20%. The ECF comprises interstitial fluid (IF) (15% of the TBW), and the remaining 5% of the TBW comprises intravascular plasma (Figures 1 and 2) [2, 3, 4]. This distribution of body fluids can have an impact on the management of pediatric gastroenteritis, as most of the fluid loss in AGE comes from the ECF. This matters because ECF contains a lot of sodium (135–145 mEq), and ICF contains a lot of potassium (150 mEq). In a brief duration of illness (<3 days), 80% of the deficit is typically from the ECF. After more than 3 days of illness, the deficit from the ECF decreases to 60%. Fluid losses for longer than 7 days are equally lost from ECF (50%) and ICF (50%) [5].
The percentage distribution of body fluids in the various compartments in a 1-year-old infant [2].
Body water compartments in relation to age [2, 3, 4].
Accurate and quick assessment of the degree of dehydration is important for proper treatment and disposition of infants and children with AGE [6]. The percentage of weight loss is the best measure to assess the degree of dehydration, as shown in Eq. (1). However, this method is impractical because in most patients the pre-illness weight is not known [7].
Current validated dehydration scales may help in assessing the versatile presentations of dehydration more objectively. Most of them illustrate clinical signs that can be assessed easily and rapidly, which can facilitate stratification of patients into dehydration categories. There are three clinical scales designed to estimate dehydration severity in children below 5 years of age: the World Health Organization (WHO) scale (Table 1), the Gorelick scale (Table 2), and the Clinical Dehydration Scale (CDS) (Table 3) [8, 9, 10].
Characteristics | No dehydration | Some dehydration (>1 sign) | Severe dehydration (>1 sign) |
---|---|---|---|
Alertness | Well, alert | Irritable or drowsy | Lethargic or poorly responsive |
Eyes | Normal | Sunken | Sunken |
Thirst | Drinks normally | Drinks eagerly | Poor or weak drinking |
Skin turgor | Goes back quickly | Goes back slowly (<2 s) | Return very slowly (>2 s) |
WHO scale for dehydration in children aged 1 month–5 years old.
Characteristics | No or minimal dehydration | Moderate-to-severe dehydration |
---|---|---|
General appearance | Alert | Restless, lethargic, unconscious |
Capillary refill | Normal | Prolonged or minimal |
Tears | Present | Absent |
Mucous membranes | Moist | Dry, very dry |
Gorelick (4-item) scale for dehydration in children aged 1 month–5 years. Scoring: ≥2 clinical signs indicates ≥ 5% loss of body weight from baseline (moderate dehydration), and ≥3 clinical signs indicates ≥ 10% loss of body weight from baseline (severe dehydration). The presence of two or more of these signs had a sensitivity of 79% and a specificity of 87% in predicting 5% dehydration.
Characteristics | Score of 0 | Score of 1 | Score of 2 |
---|---|---|---|
General appearance | Normal | Thirsty, restless, or lethargic but irritable when touched | Drowsy, limp, cold, sweaty ± comatose |
Eyes | Normal | Slightly sunken | Very sunken |
Mouth and tongue | Moist | Sticky | Dry |
Tears | Present | Decreased | Absent |
Clinical dehydration scale (CDS) for children aged 1 month–3 years. Scoring: ≥2 clinical signs indicates ≥ 5% loss of body weight from baseline (moderate dehydration), and ≥3 clinical signs indicates ≥ 10% loss of body weight from baseline (severe dehydration). The presence of two or more of these signs had a sensitivity of 79% and a specificity of 87% in predicting 5% dehydration.
Using common tools to evaluate and assess dehydration would be more helpful in day-to-day practice. Consistent evidence supports the CDS which is more useful and easy to use in assessing dehydration. This scale in combination with other criteria should be used to guide the proper medical interventions in individual cases [11]. Clinical dehydration scales are imprecise and of limited diagnostic value in children with gastroenteritis [12]. As a screening test of dehydration, historical points are moderately sensitive. Classification of dehydration into NO, SOME, and SEVERE are recommended by WHO and other groups [1, 8].
Prolonged capillary refill time, abnormal skin turgor, and abnormal respiratory pattern still remain the best three individual examination signs for assessment of dehydration. Increased capillary refill time was the strongest individual sign as an isolated finding to predict dehydration, and the poor predictor of dehydration was reduced urine output. Combinations of signs perform much better than individual signs. History taking and laboratory tests show limited utility [13].
Blood biochemistry is generally not accurate and not routinely required for assessment of dehydration. Commonly done laboratory tests such as blood urea nitrogen (BUN) and bicarbonate concentrations are generally helpful only when the results are markedly abnormal. A normal serum bicarbonate concentration of more than 15 or 17 mEq/L appears to be valuable in reducing the likelihood of dehydration. These laboratory tests done for assessing dehydration should not be considered definitive, which could be reserved for children requiring IV fluids and suffering from severe dehydration, altered conscious state or convulsions, suspected hypernatremia, suspicion of hemolytic uremic syndrome and children with pre-existing medical conditions that predispose to electrolyte abnormalities [14, 15]. Historical points and laboratory tests only have limited utility for assessing dehydration [10]. Laboratory investigations should be performed if the results will influence the management and outcome of a specific patient.
Oral rehydration should be the first line of treatment for pediatric gastroenteritis with intravenous (IV) fluid therapy being used if the oral route fails [16, 17].
Oral rehydration is the preferred method for replacing fluid and electrolyte deficits resulting from dehydration secondary to acute gastroenteritis. ORT is a safe, easy-to-use, efficacious, and cost-effective alternative to intravenous rehydration for uncomplicated gastroenteritis in children [18].
The use of ORT is based on the principle of glucose-facilitated sodium transport across the intestinal mucosa. The ORT facilitates the absorption of water and sodium for the compensation of fluid losses. Additionally, the absorption can be adequate for the replacement of significant fluid loss, such as in cholera. The absorption of potassium and bicarbonate is maintained by the osmotic gradient in the intercellular space. Metabolic acidosis, usually associated with dehydration, can be safely corrected by this mechanism. The currently available ORT contains an appropriate amount of sodium, glucose, and other electrolytes and is of appropriate osmolality to maximize clinical efficacy [19].
The WHO, Centers for Disease Control (CDC), and the American Academy of Pediatrics (AAP) all support the use of ORT for some (mild–moderate) dehydration [8, 20, 21]. Rapid ORT in mild dehydration is done by giving 50 ml/kg over 4 hours. For moderate dehydration, 100 ml/kg can be given over the same duration. Generally, children being enterally rehydrated do not require blood tests.
Children who received oral ondansetron initially were less likely to be administered IV rehydration compared with those given placebo. In addition, both oral and IV ondansetron administration are associated with reduced rate of hospitalization [17]. Ondansetron is contraindicated in children with long QT syndrome, concomitant drugs that prolong QT, and to be used cautiously in children with heart disease.
Children can be discharged home when the following levels of recovery are achieved: satisfactory rehydration status as shown by clinical improvement, IV or NG fluids not required, and no significant losses. Adequate family education, proper instructions, and medical follow-up should be provided.
Inform about the expected natural course of the illness, prevention of transmission and looking at signs of dehydration. Encourage breastfeeding continuation in small babies, early refeeding, and the correct method of preparing ORS. Educate about the importance of giving anti-rotavirus vaccination and of course not to use unnecessary medication in simple AGE.
Nasogastric route is a safe rehydration technique with minimal adverse effects which has been adequately studied. Many clinical trials showed this method to have similar efficacy compared to IV therapy. Rapid NG rehydration using gastrolyte, 50 ml/kg for fluid deficit replacement over 4 hours, appears to be appropriate for children with mild-to-moderate dehydration [22]. If nasogastric rehydration is required beyond 4 hours, check urea and electrolyte concentration (UEC) and blood glucose level (BGL), and reassess the patient for hydration status.
Intravenous rehydration should be reserved for patients with severe dehydration or shock and for those with some (mild-to-moderate) dehydration who fail ORT. Fluid containing not less than 0.9% sodium chloride is preferred for rehydration [23, 24]. Using hypotonic fluids predisposes for dilutional hyponatremia due to excess antidiuretic hormone (ADH) secretion in children with AGE. Serum electrolytes and BGL are required in children with severe dehydration and/or requiring IV fluid therapy for correction of dehydration.
The WHO recommends IV rehydration to be rapidly completed over 3–4 hours [8]. Rapid replacement of ECF improves gastrointestinal and renal perfusion, allowing earlier oral intake and a faster correction of electrolyte and acid-base abnormalities, which results in excellent recovery rate and decreased length of stay in ED [25].
Resuscitate shock/near shock with a prompt intravenous infusion of 20 ml/kg of 0.9% sodium chloride solution or Ringer’s lactate solution as fast as possible. Reassessing and repeating boluses given, as necessary, are required until the patient is recovered from shock and then followed by maintenance IV fluids [26].
The clinical standard is to administer 20 mL/kg/h of isotonic crystalloid fluid, such as 0.9% normal saline or lactated Ringer’s solution. Reassess the patient after each bolus, and if the patient is still dehydrated, a total of 2–4 fluid boluses may allow rapid restoration of intravascular volume which can bring rapid recovery. Rapid IV rehydration followed by oral fluids is adequate for initial rehydration for most patients requiring IV fluid therapy. For those refusing oral intake, continuous infusion of maintenance IV fluids are to be given until oral fluids are tolerated [27]. Glucose solution should be added once ECF volume has been restored and addition of potassium considered once the child passes urine and serum electrolytes are known [28].
Refer to the correction of dehydration using a large volume of fluids over a relatively shorter time (50–60 ml/kg/hour). Ultra-rapid IV rehydration may be associated with electrolyte abnormalities and longer hospital stay or delayed discharge and therefore is not recommended [29, 30].
Children with acute watery diarrhea and severe dehydration, such as cholera, who fail ORT, can benefit from large-volume IV rehydration (100 ml/kg) of Ringer’s lactate solution or normal saline over 3–6 hours. Frequent reassessment is required, and if hydration status is not improving, IV fluids should be given more rapidly [31]. Further research investigations are needed to justify the use of rapid large-volume IV rehydration in pediatric gastroenteritis.
Dyselectrolytemia is a serious complication of AGE with dehydration. The majority of electrolyte disorders associated with AGE in children can be adequately treated using ORT.
Hypernatremia leads to hypertonicity that can be potentially dangerous as there is a greater likelihood of neurological manifestations. Most frequently, it is due to water deficit from increased water losses in diarrhea and due to reduced water intake during the illness.
As in any type of dehydration, the primary aim should be restoration of hemodynamic stability by administration of isotonic fluids. The gradual replacement of water deficit remains the gold standard treatment for hypernatremic dehydration [32]. The recent advance in management of hypernatremia is to give isotonic (0.9% sodium chloride + 5% glucose) than hypotonic solution to correct the calculated fluid deficit slowly. The more the solution contains free water, the higher the risk of developing hyponatremia during rehydration [23, 33].
It represents an excess of water in relation to sodium in ECF [34]. Hyponatremia is seldom symptomatic unless the serum Na is <120 or if the hyponatremia occurs quickly [35]. Hyponatremia may be presented with nausea, vomiting, headache, irritability, lethargy, confusion, muscle cramps, convulsions, disorientation, and reduced consciousness and places the patient at risk of neurologic impairment [36].
The initial goal in treating hyponatremia is the restoration of intravascular volume with isotonic saline and to be followed by a slower correction using 0.9% sodium chloride + 5% glucose. In severe hyponatremia or symptomatic children, the goal is to raise the serum sodium to 120–125 mmol/L or until the seizure stops [35]. As a rule of thumb, IV infusion of 3% NaCl, 3–5 ml/kg over 15–30 min, will raise serum Na by 5 mEq/L.
See Figure 3.
Flow chart for the management of pediatric gastroenteritis with dehydration.
The management of a child with a dehydrating gastroenteritis requires careful initial assessment and reassessment of hydration status. The majority of gastroenteritis in infants and children are simple and can be treated by ORT. In children who presented with severe dehydration or those with some dehydration and fail ORT, IV rehydration is required. Rapid IV rehydration using standard boluses of isotonic fluids followed by oral fluid intake or maintenance IV fluids for those refusing oral intake appears sufficient for most patients requiring IV fluids. Patients achieving satisfactory hydration status and tolerating oral intake can be discharge home with proper instructions.
The authors thank physicians and nurses staff who are working at the Pediatric Emergency center (PEC) Alsadd, Hamad Medical Corporation (HMC), Qatar, for their help and support.
The authors declare no conflict of interest.
AGE | acute gastroenteritis |
TBW | total body water |
ECF | extracellular fluid |
ICF | intracellular fluid |
UEC | urea electrolyte concentration |
BGL | blood glucose level |
ORT | oral rehydration therapy |
IV | intravenous |
ADH | antidiuretic hormone |
NICE | National Institute for Health and Care Excellence |
ED | emergency department |
If you are associated with any of the institutions in our list below, you can apply to receive OA publication funds by following the instructions provided in the links.
",metaTitle:"List of Institutions by Country",metaDescription:"If you are associated with any of the institutions in our list below, you can apply to receive OA publication funds by following the instructions provided in the links. However, if your research is financed through any of the below-mentioned funders, please consult their Open Access policies or grant ‘terms and conditions’ to explore ways to cover your publication costs (also accessible by clicking on the link in their title).",metaKeywords:null,canonicalURL:"open-access-funding-institutions-list",contentRaw:'[{"type":"htmlEditorComponent","content":"Book Chapters and Monographs
\\n\\nBook Chapters
\\n\\nMonographs Only
\\n\\n\\n\\nBook Chapters and Monographs
\\n\\nMonographs Only
\\n\\nBook Chapters and Monographs
\\n\\n\\n\\nBook Chapters and Monographs
\\n\\n\\n\\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\\n\\nCSIC affiliated authors can also take advantage of a central Open Access fund (amounting to 10,000 EUR) to cover up to 50% of the rest of the OAPF until it expires. Effective for chapters accepted from January 1, 2020.
\\n\\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\\n\\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\\n\\n\\n\\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nBook Chapters and Monographs
\\n\\nThe Claremont Colleges are pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\\n\\nCorresponding authors will receive a 15% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\\n\\nThe University of Massachusetts, Amherst is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\\n\\nCorresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\\n\\nThe University of Surrey is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\\n\\nCorresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\\n\\nMonographs Only
\\n\\n\\n\\nImportant: You must be a member or grantee of the above listed institutions in order to apply for their Open Access publication funds.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'Book Chapters and Monographs
\n\n\n\nBook Chapters
\n\nMonographs Only
\n\n\n\nBook Chapters and Monographs
\n\nMonographs Only
\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\n\n\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\n\nCSIC affiliated authors can also take advantage of a central Open Access fund (amounting to 10,000 EUR) to cover up to 50% of the rest of the OAPF until it expires. Effective for chapters accepted from January 1, 2020.
\n\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\n\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\n\n\n\nCorresponding authors will receive a 25% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters. A 20% discount for publishing a long-form monographs, 25% for compacts and 23% for short-form monographs.
\n\nBook Chapters and Monographs
\n\nBook Chapters and Monographs
\n\nBook Chapters and Monographs
\n\n\n\nBook Chapters and Monographs
\n\nThe Claremont Colleges are pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\n\nCorresponding authors will receive a 15% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\n\nThe University of Massachusetts, Amherst is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\n\nCorresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\n\nThe University of Surrey is pledging funds via the Knowledge Unlatched program to ensure academics can publish Open Access content more easily.
\n\nCorresponding authors will receive a 10% discount on their Open Access Publication Fees (OAPF) for Open Access book chapters or monograph publications. To use the discount you will need to verify your institutional email address. These discounts are valid from 2020 to 2022.
\n\nMonographs Only
\n\n\n\nImportant: You must be a member or grantee of the above listed institutions in order to apply for their Open Access publication funds.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5774},{group:"region",caption:"Middle and South America",value:2,count:5239},{group:"region",caption:"Africa",value:3,count:1721},{group:"region",caption:"Asia",value:4,count:10411},{group:"region",caption:"Australia and Oceania",value:5,count:897},{group:"region",caption:"Europe",value:6,count:15810}],offset:12,limit:12,total:118377},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"16"},books:[{type:"book",id:"9816",title:"Idiopathic Pulmonary Fibrosis",subtitle:null,isOpenForSubmission:!0,hash:"365bb9762ba33db2d07e677690af1772",slug:null,bookSignature:"Dr. Salim Surani and Dr. Venkat Rajasurya",coverURL:"https://cdn.intechopen.com/books/images_new/9816.jpg",editedByType:null,editors:[{id:"15654",title:"Dr.",name:"Salim",surname:"Surani",slug:"salim-surani",fullName:"Salim Surani"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10231",title:"Proton Therapy",subtitle:null,isOpenForSubmission:!0,hash:"f4a9009287953c8d1d89f0fa9b7597b0",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10231.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10343",title:"Ocular Hypertension",subtitle:null,isOpenForSubmission:!0,hash:"0ff71cc7e0d9f394f41162c0c825588a",slug:null,bookSignature:"Prof. Michele Lanza",coverURL:"https://cdn.intechopen.com/books/images_new/10343.jpg",editedByType:null,editors:[{id:"240088",title:"Prof.",name:"Michele",surname:"Lanza",slug:"michele-lanza",fullName:"Michele Lanza"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10704",title:"Cardiac Arrhythmias - Translational Approach from Pathophysiology to Advanced Care",subtitle:null,isOpenForSubmission:!0,hash:"0e5d67464d929fda6d8c83ec20c4138a",slug:null,bookSignature:"Dr. Endre Zima",coverURL:"https://cdn.intechopen.com/books/images_new/10704.jpg",editedByType:null,editors:[{id:"201263",title:"Dr.",name:"Endre",surname:"Zima",slug:"endre-zima",fullName:"Endre Zima"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10705",title:"Healthcare Access",subtitle:null,isOpenForSubmission:!0,hash:"e8e9561a91e5f7771932aa5d49c3b687",slug:null,bookSignature:"Prof. Amit Agrawal and Dr. Srinivas Kosgi",coverURL:"https://cdn.intechopen.com/books/images_new/10705.jpg",editedByType:null,editors:[{id:"100142",title:"Prof.",name:"Amit",surname:"Agrawal",slug:"amit-agrawal",fullName:"Amit Agrawal"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10706",title:"Fighting the COVID-19 Pandemic",subtitle:null,isOpenForSubmission:!0,hash:"1a5246f0b6ba4f0e9ad1fbfa4134c598",slug:null,bookSignature:"Dr. Manal Mohammad Baddour",coverURL:"https://cdn.intechopen.com/books/images_new/10706.jpg",editedByType:null,editors:[{id:"174598",title:"Dr.",name:"Manal Mohammad",surname:"Baddour",slug:"manal-mohammad-baddour",fullName:"Manal Mohammad Baddour"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10707",title:"Primary Care",subtitle:null,isOpenForSubmission:!0,hash:"bdb1aeb61b1eb116c1bdb09d25593686",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10707.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10708",title:"Topics in Regional Anesthesia",subtitle:null,isOpenForSubmission:!0,hash:"264f7f37033b4867cace7912287fccaa",slug:null,bookSignature:"Prof. Víctor M. Whizar-Lugo and Dr. José Ramón Saucillo-Osuna",coverURL:"https://cdn.intechopen.com/books/images_new/10708.jpg",editedByType:null,editors:[{id:"169249",title:"Prof.",name:"Víctor M.",surname:"Whizar-Lugo",slug:"victor-m.-whizar-lugo",fullName:"Víctor M. Whizar-Lugo"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10709",title:"Heart Valve Surgery",subtitle:null,isOpenForSubmission:!0,hash:"cb3479fd272d968ee7eee95ae09ea9db",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10709.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10710",title:"Recent Advances in the Treatment of Orofacial Clefts",subtitle:null,isOpenForSubmission:!0,hash:"ec438b5e4be44dc63870c1ace6a56ed2",slug:null,bookSignature:"Dr. Marcos Roberto Tovani Palone",coverURL:"https://cdn.intechopen.com/books/images_new/10710.jpg",editedByType:null,editors:[{id:"221178",title:"Dr.",name:"Marcos Roberto",surname:"Tovani Palone",slug:"marcos-roberto-tovani-palone",fullName:"Marcos Roberto Tovani Palone"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10711",title:"Arthroscopy",subtitle:null,isOpenForSubmission:!0,hash:"afa83f11ba2442e7612f5b8c6aa3c659",slug:null,bookSignature:"M.D. Carlos Suarez-Ahedo",coverURL:"https://cdn.intechopen.com/books/images_new/10711.jpg",editedByType:null,editors:[{id:"235976",title:"M.D.",name:"Carlos",surname:"Suarez-Ahedo",slug:"carlos-suarez-ahedo",fullName:"Carlos Suarez-Ahedo"}],productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10712",title:"Thrombectomy",subtitle:null,isOpenForSubmission:!0,hash:"853e71d74c3dd5007277d3770e639d47",slug:null,bookSignature:"",coverURL:"https://cdn.intechopen.com/books/images_new/10712.jpg",editedByType:null,editors:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:18},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:5},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:8},{group:"topic",caption:"Computer and Information Science",value:9,count:6},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:7},{group:"topic",caption:"Engineering",value:11,count:20},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:25},{group:"topic",caption:"Neuroscience",value:18,count:2},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:3},{group:"topic",caption:"Physics",value:20,count:3},{group:"topic",caption:"Psychology",value:21,count:4},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:1}],offset:12,limit:12,total:51},popularBooks:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9027",title:"Human Blood Group Systems and Haemoglobinopathies",subtitle:null,isOpenForSubmission:!1,hash:"d00d8e40b11cfb2547d1122866531c7e",slug:"human-blood-group-systems-and-haemoglobinopathies",bookSignature:"Osaro Erhabor and Anjana Munshi",coverURL:"https://cdn.intechopen.com/books/images_new/9027.jpg",editors:[{id:"35140",title:null,name:"Osaro",middleName:null,surname:"Erhabor",slug:"osaro-erhabor",fullName:"Osaro Erhabor"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8558",title:"Aerodynamics",subtitle:null,isOpenForSubmission:!1,hash:"db7263fc198dfb539073ba0260a7f1aa",slug:"aerodynamics",bookSignature:"Mofid Gorji-Bandpy and Aly-Mousaad Aly",coverURL:"https://cdn.intechopen.com/books/images_new/8558.jpg",editors:[{id:"35542",title:"Prof.",name:"Mofid",middleName:null,surname:"Gorji-Bandpy",slug:"mofid-gorji-bandpy",fullName:"Mofid Gorji-Bandpy"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5249},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9385",title:"Renewable Energy",subtitle:"Technologies and Applications",isOpenForSubmission:!1,hash:"a6b446d19166f17f313008e6c056f3d8",slug:"renewable-energy-technologies-and-applications",bookSignature:"Tolga Taner, Archana Tiwari and Taha Selim Ustun",coverURL:"https://cdn.intechopen.com/books/images_new/9385.jpg",editors:[{id:"197240",title:"Associate Prof.",name:"Tolga",middleName:null,surname:"Taner",slug:"tolga-taner",fullName:"Tolga Taner"}],equalEditorOne:{id:"186791",title:"Dr.",name:"Archana",middleName:null,surname:"Tiwari",slug:"archana-tiwari",fullName:"Archana Tiwari",profilePictureURL:"https://mts.intechopen.com/storage/users/186791/images/system/186791.jpg",biography:"Dr. Archana Tiwari is Associate Professor at Amity University, India. Her research interests include renewable sources of energy from microalgae and further utilizing the residual biomass for the generation of value-added products, bioremediation through microalgae and microbial consortium, antioxidative enzymes and stress, and nutraceuticals from microalgae. She has been working on algal biotechnology for the last two decades. She has published her research in many international journals and has authored many books and chapters with renowned publishing houses. She has also delivered talks as an invited speaker at many national and international conferences. Dr. Tiwari is the recipient of several awards including Researcher of the Year and Distinguished Scientist.",institutionString:"Amity University",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"1",institution:{name:"Amity University",institutionURL:null,country:{name:"India"}}},equalEditorTwo:{id:"197609",title:"Prof.",name:"Taha Selim",middleName:null,surname:"Ustun",slug:"taha-selim-ustun",fullName:"Taha Selim Ustun",profilePictureURL:"https://mts.intechopen.com/storage/users/197609/images/system/197609.jpeg",biography:"Dr. Taha Selim Ustun received a Ph.D. in Electrical Engineering from Victoria University, Melbourne, Australia. He is a researcher with the Fukushima Renewable Energy Institute, AIST (FREA), where he leads the Smart Grid Cybersecurity Laboratory. Prior to that, he was a faculty member with the School of Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA, USA. His current research interests include power systems protection, communication in power networks, distributed generation, microgrids, electric vehicle integration, and cybersecurity in smart grids. He serves on the editorial boards of IEEE Access, IEEE Transactions on Industrial Informatics, Energies, Electronics, Electricity, World Electric Vehicle and Information journals. Dr. Ustun is a member of the IEEE 2004 and 2800, IEC Renewable Energy Management WG 8, and IEC TC 57 WG17. He has been invited to run specialist courses in Africa, India, and China. He has delivered talks for the Qatar Foundation, the World Energy Council, the Waterloo Global Science Initiative, and the European Union Energy Initiative (EUEI). His research has attracted funding from prestigious programs in Japan, Australia, the European Union, and North America.",institutionString:"Fukushima Renewable Energy Institute, AIST (FREA)",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"1",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"National Institute of Advanced Industrial Science and Technology",institutionURL:null,country:{name:"Japan"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8985",title:"Natural Resources Management and Biological Sciences",subtitle:null,isOpenForSubmission:!1,hash:"5c2e219a6c021a40b5a20c041dea88c4",slug:"natural-resources-management-and-biological-sciences",bookSignature:"Edward R. Rhodes and Humood Naser",coverURL:"https://cdn.intechopen.com/books/images_new/8985.jpg",editors:[{id:"280886",title:"Prof.",name:"Edward R",middleName:null,surname:"Rhodes",slug:"edward-r-rhodes",fullName:"Edward R Rhodes"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9644",title:"Glaciers and the Polar Environment",subtitle:null,isOpenForSubmission:!1,hash:"e8cfdc161794e3753ced54e6ff30873b",slug:"glaciers-and-the-polar-environment",bookSignature:"Masaki Kanao, Danilo Godone and Niccolò Dematteis",coverURL:"https://cdn.intechopen.com/books/images_new/9644.jpg",editors:[{id:"51959",title:"Dr.",name:"Masaki",middleName:null,surname:"Kanao",slug:"masaki-kanao",fullName:"Masaki Kanao"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7847",title:"Medical Toxicology",subtitle:null,isOpenForSubmission:!1,hash:"db9b65bea093de17a0855a1b27046247",slug:"medical-toxicology",bookSignature:"Pınar Erkekoglu and Tomohisa Ogawa",coverURL:"https://cdn.intechopen.com/books/images_new/7847.jpg",editors:[{id:"109978",title:"Prof.",name:"Pınar",middleName:null,surname:"Erkekoglu",slug:"pinar-erkekoglu",fullName:"Pınar Erkekoglu"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"9243",title:"Coastal Environments",subtitle:null,isOpenForSubmission:!1,hash:"8e05e5f631e935eef366980f2e28295d",slug:"coastal-environments",bookSignature:"Yuanzhi Zhang and X. San Liang",coverURL:"https://cdn.intechopen.com/books/images_new/9243.jpg",editedByType:"Edited by",editors:[{id:"77597",title:"Prof.",name:"Yuanzhi",middleName:null,surname:"Zhang",slug:"yuanzhi-zhang",fullName:"Yuanzhi Zhang"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10020",title:"Operations Management",subtitle:"Emerging Trend in the Digital Era",isOpenForSubmission:!1,hash:"526f0dbdc7e4d85b82ce8383ab894b4c",slug:"operations-management-emerging-trend-in-the-digital-era",bookSignature:"Antonella Petrillo, Fabio De Felice, Germano Lambert-Torres and Erik Bonaldi",coverURL:"https://cdn.intechopen.com/books/images_new/10020.jpg",editedByType:"Edited by",editors:[{id:"181603",title:"Dr.",name:"Antonella",middleName:null,surname:"Petrillo",slug:"antonella-petrillo",fullName:"Antonella Petrillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9521",title:"Antimicrobial Resistance",subtitle:"A One Health Perspective",isOpenForSubmission:!1,hash:"30949e78832e1afba5606634b52056ab",slug:"antimicrobial-resistance-a-one-health-perspective",bookSignature:"Mihai Mareș, Swee Hua Erin Lim, Kok-Song Lai and Romeo-Teodor Cristina",coverURL:"https://cdn.intechopen.com/books/images_new/9521.jpg",editedByType:"Edited by",editors:[{id:"88785",title:"Prof.",name:"Mihai",middleName:null,surname:"Mares",slug:"mihai-mares",fullName:"Mihai Mares"}],equalEditorOne:{id:"190224",title:"Dr.",name:"Swee Hua Erin",middleName:null,surname:"Lim",slug:"swee-hua-erin-lim",fullName:"Swee Hua Erin Lim",profilePictureURL:"https://mts.intechopen.com/storage/users/190224/images/system/190224.png",biography:"Dr. Erin Lim is presently working as an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates and is affiliated as an Associate Professor to Perdana University-Royal College of Surgeons in Ireland, Selangor, Malaysia. She obtained her Ph.D. from Universiti Putra Malaysia in 2010 with a National Science Fellowship awarded from the Ministry of Science, Technology and Innovation Malaysia and has been actively involved in research ever since. Her main research interests include analysis of carriage and transmission of multidrug resistant bacteria in non-conventional settings, besides an interest in natural products for antimicrobial testing. She is heavily involved in the elucidation of mechanisms of reversal of resistance in bacteria in addition to investigating the immunological analyses of diseases, development of vaccination and treatment models in animals. She hopes her work will support the discovery of therapeutics in the clinical setting and assist in the combat against the burden of antibiotic resistance.",institutionString:"Abu Dhabi Women’s College",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"3",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Perdana University",institutionURL:null,country:{name:"Malaysia"}}},equalEditorTwo:{id:"221544",title:"Dr.",name:"Kok-Song",middleName:null,surname:"Lai",slug:"kok-song-lai",fullName:"Kok-Song Lai",profilePictureURL:"https://mts.intechopen.com/storage/users/221544/images/system/221544.jpeg",biography:"Dr. Lai Kok Song is an Assistant Professor in the Division of Health Sciences, Abu Dhabi Women\\'s College, Higher Colleges of Technology in Abu Dhabi, United Arab Emirates. He obtained his Ph.D. in Biological Sciences from Nara Institute of Science and Technology, Japan in 2012. Prior to his academic appointment, Dr. Lai worked as a Senior Scientist at the Ministry of Science, Technology and Innovation, Malaysia. His current research areas include antimicrobial resistance and plant-pathogen interaction. His particular interest lies in the study of the antimicrobial mechanism via membrane disruption of essential oils against multi-drug resistance bacteria through various biochemical, molecular and proteomic approaches. Ultimately, he hopes to uncover and determine novel biomarkers related to antibiotic resistance that can be developed into new therapeutic strategies.",institutionString:"Higher Colleges of Technology",position:null,outsideEditionCount:0,totalCites:0,totalAuthoredChapters:"8",totalChapterViews:"0",totalEditedBooks:"0",institution:{name:"Higher Colleges of Technology",institutionURL:null,country:{name:"United Arab Emirates"}}},equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9560",title:"Creativity",subtitle:"A Force to Innovation",isOpenForSubmission:!1,hash:"58f740bc17807d5d88d647c525857b11",slug:"creativity-a-force-to-innovation",bookSignature:"Pooja Jain",coverURL:"https://cdn.intechopen.com/books/images_new/9560.jpg",editedByType:"Edited by",editors:[{id:"316765",title:"Dr.",name:"Pooja",middleName:null,surname:"Jain",slug:"pooja-jain",fullName:"Pooja Jain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9669",title:"Recent Advances in Rice Research",subtitle:null,isOpenForSubmission:!1,hash:"12b06cc73e89af1e104399321cc16a75",slug:"recent-advances-in-rice-research",bookSignature:"Mahmood-ur- Rahman Ansari",coverURL:"https://cdn.intechopen.com/books/images_new/9669.jpg",editedByType:"Edited by",editors:[{id:"185476",title:"Dr.",name:"Mahmood-Ur-",middleName:null,surname:"Rahman Ansari",slug:"mahmood-ur-rahman-ansari",fullName:"Mahmood-Ur- Rahman Ansari"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10192",title:"Background and Management of Muscular Atrophy",subtitle:null,isOpenForSubmission:!1,hash:"eca24028d89912b5efea56e179dff089",slug:"background-and-management-of-muscular-atrophy",bookSignature:"Julianna Cseri",coverURL:"https://cdn.intechopen.com/books/images_new/10192.jpg",editedByType:"Edited by",editors:[{id:"135579",title:"Dr.",name:"Julianna",middleName:null,surname:"Cseri",slug:"julianna-cseri",fullName:"Julianna Cseri"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9550",title:"Entrepreneurship",subtitle:"Contemporary Issues",isOpenForSubmission:!1,hash:"9b4ac1ee5b743abf6f88495452b1e5e7",slug:"entrepreneurship-contemporary-issues",bookSignature:"Mladen Turuk",coverURL:"https://cdn.intechopen.com/books/images_new/9550.jpg",editedByType:"Edited by",editors:[{id:"319755",title:"Prof.",name:"Mladen",middleName:null,surname:"Turuk",slug:"mladen-turuk",fullName:"Mladen Turuk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10065",title:"Wavelet Theory",subtitle:null,isOpenForSubmission:!1,hash:"d8868e332169597ba2182d9b004d60de",slug:"wavelet-theory",bookSignature:"Somayeh Mohammady",coverURL:"https://cdn.intechopen.com/books/images_new/10065.jpg",editedByType:"Edited by",editors:[{id:"109280",title:"Dr.",name:"Somayeh",middleName:null,surname:"Mohammady",slug:"somayeh-mohammady",fullName:"Somayeh Mohammady"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9313",title:"Clay Science and Technology",subtitle:null,isOpenForSubmission:!1,hash:"6fa7e70396ff10620e032bb6cfa6fb72",slug:"clay-science-and-technology",bookSignature:"Gustavo Morari Do Nascimento",coverURL:"https://cdn.intechopen.com/books/images_new/9313.jpg",editedByType:"Edited by",editors:[{id:"7153",title:"Prof.",name:"Gustavo",middleName:null,surname:"Morari Do Nascimento",slug:"gustavo-morari-do-nascimento",fullName:"Gustavo Morari Do Nascimento"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9888",title:"Nuclear Power Plants",subtitle:"The Processes from the Cradle to the Grave",isOpenForSubmission:!1,hash:"c2c8773e586f62155ab8221ebb72a849",slug:"nuclear-power-plants-the-processes-from-the-cradle-to-the-grave",bookSignature:"Nasser Awwad",coverURL:"https://cdn.intechopen.com/books/images_new/9888.jpg",editedByType:"Edited by",editors:[{id:"145209",title:"Prof.",name:"Nasser",middleName:"S",surname:"Awwad",slug:"nasser-awwad",fullName:"Nasser Awwad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"1410",title:"Viticulture",slug:"agricultural-and-biological-sciences-viticulture",parent:{title:"Agricultural and Biological Sciences",slug:"agricultural-and-biological-sciences"},numberOfBooks:2,numberOfAuthorsAndEditors:122,numberOfWosCitations:38,numberOfCrossrefCitations:26,numberOfDimensionsCitations:61,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"agricultural-and-biological-sciences-viticulture",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"8054",title:"Advances in Grape and Wine Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"f6b9b3b3d887ed9e7c0ad09cb07edf2b",slug:"advances-in-grape-and-wine-biotechnology",bookSignature:"Antonio Morata and Iris Loira",coverURL:"https://cdn.intechopen.com/books/images_new/8054.jpg",editedByType:"Edited by",editors:[{id:"180952",title:"Prof.",name:"Antonio",middleName:null,surname:"Morata",slug:"antonio-morata",fullName:"Antonio Morata"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6077",title:"Grapes and Wines",subtitle:"Advances in Production, Processing, Analysis and Valorization",isOpenForSubmission:!1,hash:"61fe601d66e441800c8ed9503f86280f",slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",bookSignature:"António Manuel Jordão and Fernanda Cosme",coverURL:"https://cdn.intechopen.com/books/images_new/6077.jpg",editedByType:"Edited by",editors:[{id:"186821",title:"Dr.",name:"António",middleName:null,surname:"M. Jordão",slug:"antonio-m.-jordao",fullName:"António M. Jordão"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:2,mostCitedChapters:[{id:"58633",doi:"10.5772/intechopen.72800",title:"The Evolution of Polyphenols from Grapes to Wines",slug:"the-evolution-of-polyphenols-from-grapes-to-wines",totalDownloads:1328,totalCrossrefCites:3,totalDimensionsCites:7,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Violeta-Carolina Niculescu, Nadia Paun and Roxana-Elena Ionete",authors:[{id:"187102",title:"Dr.",name:"Roxana",middleName:null,surname:"Ionete",slug:"roxana-ionete",fullName:"Roxana Ionete"},{id:"206056",title:"Dr.",name:"Violeta",middleName:"Carolina",surname:"Niculescu",slug:"violeta-niculescu",fullName:"Violeta Niculescu"},{id:"207020",title:"Mrs.",name:"Nadia",middleName:null,surname:"Paun",slug:"nadia-paun",fullName:"Nadia Paun"}]},{id:"59216",doi:"10.5772/intechopen.73132",title:"Potential for Use of the Residues of the Wine Industry in Human Nutrition and as Agricultural Input",slug:"potential-for-use-of-the-residues-of-the-wine-industry-in-human-nutrition-and-as-agricultural-input",totalDownloads:945,totalCrossrefCites:2,totalDimensionsCites:5,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Renato Vasconcelos Botelho, Gabriela Datsch Bennemann,\nYohandra Reyes Torres and Alessandro Jefferson Sato",authors:[{id:"64335",title:"Prof.",name:"Renato",middleName:"Vasconcelos",surname:"Botelho",slug:"renato-botelho",fullName:"Renato Botelho"},{id:"208714",title:"MSc.",name:"Gabriela",middleName:null,surname:"Datsch Bennemann",slug:"gabriela-datsch-bennemann",fullName:"Gabriela Datsch Bennemann"},{id:"208715",title:"Dr.",name:"Yohandra",middleName:null,surname:"Reyes Torres",slug:"yohandra-reyes-torres",fullName:"Yohandra Reyes Torres"},{id:"208716",title:"Dr.",name:"Alessandro Jefferson",middleName:null,surname:"Sato",slug:"alessandro-jefferson-sato",fullName:"Alessandro Jefferson Sato"}]},{id:"57946",doi:"10.5772/intechopen.71627",title:"Microbiological, Physical, and Chemical Procedures to Elaborate High-Quality SO2-Free Wines",slug:"microbiological-physical-and-chemical-procedures-to-elaborate-high-quality-so2-free-wines",totalDownloads:1088,totalCrossrefCites:3,totalDimensionsCites:5,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Raúl Ferrer-Gallego, Miquel Puxeu, Laura Martín, Enric Nart, Claudio\nHidalgo and Imma Andorrà",authors:[{id:"207221",title:"Dr.",name:"Raúl",middleName:null,surname:"Ferrer-Gallego",slug:"raul-ferrer-gallego",fullName:"Raúl Ferrer-Gallego"},{id:"208597",title:"Dr.",name:"Miquel",middleName:null,surname:"Puxeu",slug:"miquel-puxeu",fullName:"Miquel Puxeu"},{id:"208598",title:"Dr.",name:"Laura",middleName:null,surname:"Martín",slug:"laura-martin",fullName:"Laura Martín"},{id:"208599",title:"Mr.",name:"Enric",middleName:null,surname:"Nart",slug:"enric-nart",fullName:"Enric Nart"},{id:"208600",title:"Dr.",name:"Claudio",middleName:null,surname:"Hidalgo",slug:"claudio-hidalgo",fullName:"Claudio Hidalgo"},{id:"208601",title:"Dr.",name:"Imma",middleName:null,surname:"Andorrà",slug:"imma-andorra",fullName:"Imma Andorrà"}]}],mostDownloadedChaptersLast30Days:[{id:"58638",title:"Occurrence and Analysis of Sulfur Compounds in Wine",slug:"occurrence-and-analysis-of-sulfur-compounds-in-wine",totalDownloads:1193,totalCrossrefCites:1,totalDimensionsCites:3,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Daniela Fracassetti and Ileana Vigentini",authors:[{id:"207271",title:"Dr.",name:"Daniela",middleName:null,surname:"Fracassetti",slug:"daniela-fracassetti",fullName:"Daniela Fracassetti"},{id:"220967",title:"Dr.",name:"Ileana",middleName:null,surname:"Vigentini",slug:"ileana-vigentini",fullName:"Ileana Vigentini"}]},{id:"57041",title:"Fingerprints of Anthocyanins and Flavonols in Wild Grapes (Vitis vinifera L. ssp. sylvestris (Gmelin) Hegi)",slug:"fingerprints-of-anthocyanins-and-flavonols-in-wild-grapes-vitis-vinifera-l-ssp-sylvestris-gmelin-heg",totalDownloads:924,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Eugenio Revilla, Rosa Arroyo-Garcia, Alberto Bellido, David\nCarrasco, Anna Puig and Leonor Ruiz-Garcia",authors:[{id:"154744",title:"Dr.",name:"Rosa Adela",middleName:null,surname:"Arroyo-Garcia",slug:"rosa-adela-arroyo-garcia",fullName:"Rosa Adela Arroyo-Garcia"},{id:"207857",title:"Prof.",name:"Eugenio",middleName:null,surname:"Revilla",slug:"eugenio-revilla",fullName:"Eugenio Revilla"},{id:"207926",title:"Dr.",name:"Alberto",middleName:null,surname:"Bellido",slug:"alberto-bellido",fullName:"Alberto Bellido"},{id:"207927",title:"Dr.",name:"Davis",middleName:null,surname:"Carrasco",slug:"davis-carrasco",fullName:"Davis Carrasco"},{id:"207928",title:"Dr.",name:"Anna",middleName:null,surname:"Puig",slug:"anna-puig",fullName:"Anna Puig"},{id:"207929",title:"Dr.",name:"Leonor",middleName:null,surname:"Ruiz",slug:"leonor-ruiz",fullName:"Leonor Ruiz"}]},{id:"58633",title:"The Evolution of Polyphenols from Grapes to Wines",slug:"the-evolution-of-polyphenols-from-grapes-to-wines",totalDownloads:1326,totalCrossrefCites:3,totalDimensionsCites:7,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Violeta-Carolina Niculescu, Nadia Paun and Roxana-Elena Ionete",authors:[{id:"187102",title:"Dr.",name:"Roxana",middleName:null,surname:"Ionete",slug:"roxana-ionete",fullName:"Roxana Ionete"},{id:"206056",title:"Dr.",name:"Violeta",middleName:"Carolina",surname:"Niculescu",slug:"violeta-niculescu",fullName:"Violeta Niculescu"},{id:"207020",title:"Mrs.",name:"Nadia",middleName:null,surname:"Paun",slug:"nadia-paun",fullName:"Nadia Paun"}]},{id:"67039",title:"The Microvine: A Versatile Plant Model to Boost Grapevine Studies in Physiology and Genetics",slug:"the-microvine-a-versatile-plant-model-to-boost-grapevine-studies-in-physiology-and-genetics",totalDownloads:583,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"advances-in-grape-and-wine-biotechnology",title:"Advances in Grape and Wine Biotechnology",fullTitle:"Advances in Grape and Wine Biotechnology"},signatures:"Anne Pellegrino, Charles Romieu, Markus Rienth and Laurent Torregrosa",authors:[{id:"284414",title:"Prof.",name:"Laurent",middleName:null,surname:"Torregrosa",slug:"laurent-torregrosa",fullName:"Laurent Torregrosa"},{id:"285872",title:"Dr.",name:"Charles",middleName:null,surname:"Romieu",slug:"charles-romieu",fullName:"Charles Romieu"},{id:"285873",title:"Dr.",name:"Anne",middleName:null,surname:"Pellegrino",slug:"anne-pellegrino",fullName:"Anne Pellegrino"},{id:"298280",title:"Dr.",name:"Markus",middleName:null,surname:"Rienth",slug:"markus-rienth",fullName:"Markus Rienth"}]},{id:"59187",title:"Grapevine Trunk Diseases (GTDs): Impact on Table Grapes and Wine Vineyards in Chile",slug:"grapevine-trunk-diseases-gtds-impact-on-table-grapes-and-wine-vineyards-in-chile",totalDownloads:930,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Ximena Besoain",authors:[{id:"207574",title:"Prof.",name:"Ximena",middleName:null,surname:"Besoain",slug:"ximena-besoain",fullName:"Ximena Besoain"}]},{id:"58458",title:"Water Balance Indices for Tropical Wine Grapes",slug:"water-balance-indices-for-tropical-wine-grapes",totalDownloads:748,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Antônio Heriberto de Castro Teixeira, Jorge Tonietto and Janice F.\nLeivas",authors:[{id:"212840",title:"Dr.",name:"Antônio",middleName:null,surname:"Teixeira",slug:"antonio-teixeira",fullName:"Antônio Teixeira"},{id:"212843",title:"Dr.",name:"Jorge",middleName:null,surname:"Tonietto",slug:"jorge-tonietto",fullName:"Jorge Tonietto"},{id:"213180",title:"Dr.",name:"Janice",middleName:null,surname:"Leivas",slug:"janice-leivas",fullName:"Janice Leivas"}]},{id:"67760",title:"Production and Marketing of Low-Alcohol Wine",slug:"production-and-marketing-of-low-alcohol-wine",totalDownloads:735,totalCrossrefCites:0,totalDimensionsCites:2,book:{slug:"advances-in-grape-and-wine-biotechnology",title:"Advances in Grape and Wine Biotechnology",fullTitle:"Advances in Grape and Wine Biotechnology"},signatures:"Tamara Bucher, Kristine Deroover and Creina Stockley",authors:[{id:"289140",title:"Dr.",name:"Creina",middleName:null,surname:"Stockley",slug:"creina-stockley",fullName:"Creina Stockley"},{id:"289141",title:"Dr.",name:"Tamara",middleName:null,surname:"Bucher",slug:"tamara-bucher",fullName:"Tamara Bucher"},{id:"289142",title:"Ms.",name:"Kristine",middleName:null,surname:"Deroover",slug:"kristine-deroover",fullName:"Kristine Deroover"}]},{id:"57206",title:"Viticulture in Warmer Climates: Mitigating Environmental Stress in Douro Region, Portugal",slug:"viticulture-in-warmer-climates-mitigating-environmental-stress-in-douro-region-portugal",totalDownloads:1967,totalCrossrefCites:2,totalDimensionsCites:3,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Manuel Oliveira",authors:[{id:"181227",title:"Dr.",name:"Manuel",middleName:"T.",surname:"Oliveira",slug:"manuel-oliveira",fullName:"Manuel Oliveira"}]},{id:"58589",title:"Convenience of Applying of Viticulture Technique as a Function of the Water Status of the Vine-Stock",slug:"convenience-of-applying-of-viticulture-technique-as-a-function-of-the-water-status-of-the-vine-stock",totalDownloads:1023,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"grapes-and-wines-advances-in-production-processing-analysis-and-valorization",title:"Grapes and Wines",fullTitle:"Grapes and Wines - Advances in Production, Processing, Analysis and Valorization"},signatures:"Ester Gamero, Francisco Espinosa, Daniel Moreno, David Uriarte,\nMaría Henar Prieto, Inmaculada Garrido and María Esperanza\nValdés",authors:[{id:"209994",title:"Dr.",name:"Francisco",middleName:null,surname:"Espinosa",slug:"francisco-espinosa",fullName:"Francisco Espinosa"},{id:"222512",title:"Dr.",name:"Esperanza",middleName:null,surname:"Valdés",slug:"esperanza-valdes",fullName:"Esperanza Valdés"},{id:"222515",title:"Dr.",name:"David",middleName:null,surname:"Uriarte",slug:"david-uriarte",fullName:"David Uriarte"},{id:"222516",title:"Dr.",name:"Inmaculada",middleName:null,surname:"Garrido",slug:"inmaculada-garrido",fullName:"Inmaculada Garrido"},{id:"222518",title:"Dr.",name:"Esther",middleName:null,surname:"Gamero",slug:"esther-gamero",fullName:"Esther Gamero"},{id:"222519",title:"Dr.",name:"Maria-Henar",middleName:null,surname:"Prieto",slug:"maria-henar-prieto",fullName:"Maria-Henar Prieto"},{id:"222520",title:"Mr.",name:"David",middleName:null,surname:"Moreno",slug:"david-moreno",fullName:"David Moreno"}]},{id:"67444",title:"Somatic Variation and Cultivar Innovation in Grapevine",slug:"somatic-variation-and-cultivar-innovation-in-grapevine",totalDownloads:487,totalCrossrefCites:3,totalDimensionsCites:5,book:{slug:"advances-in-grape-and-wine-biotechnology",title:"Advances in Grape and Wine Biotechnology",fullTitle:"Advances in Grape and Wine Biotechnology"},signatures:"Pablo Carbonell-Bejerano, Carolina Royo, Nuria Mauri, Javier Ibáñez and José Miguel Martínez Zapater",authors:[{id:"287215",title:"Prof.",name:"Jose Miguel",middleName:null,surname:"Martinez Zapater",slug:"jose-miguel-martinez-zapater",fullName:"Jose Miguel Martinez Zapater"},{id:"287226",title:"Dr.",name:"Javier",middleName:null,surname:"Ibáñez",slug:"javier-ibanez",fullName:"Javier Ibáñez"},{id:"300441",title:"Dr.",name:"Pablo",middleName:null,surname:"Carbonell-Bejerano",slug:"pablo-carbonell-bejerano",fullName:"Pablo Carbonell-Bejerano"},{id:"300442",title:"Dr.",name:"Carolina",middleName:null,surname:"Royo",slug:"carolina-royo",fullName:"Carolina Royo"},{id:"300444",title:"Dr.",name:"Nuria",middleName:null,surname:"Mauri",slug:"nuria-mauri",fullName:"Nuria Mauri"}]}],onlineFirstChaptersFilter:{topicSlug:"agricultural-and-biological-sciences-viticulture",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/120431/fabrice-stehlin",hash:"",query:{},params:{id:"120431",slug:"fabrice-stehlin"},fullPath:"/profiles/120431/fabrice-stehlin",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()